InvestSMART

TrivarX Ltd (ASX: TRI) - Share Price

- Current share price for TRI : $0.011

TrivarX Ltd (TRI) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a mental health technology company pioneering the use of objective measures to aid in early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). The Company is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market.

TRI General Information +

ASX Code TRI
Website N/A
Industry/Sector Health Care Technology
Market Cap ($M) 12
TRI Share Price $0.011
Day High $0.012
Day Low $0.011
Last Close $0.011
TRI Share Price Movement - ( No change )
Prices as at 16:40, 3 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

TrivarX Ltd (TRI) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from TrivarX Ltd (TRI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

TrivarX Ltd (TRI) price-sensitive announcements

TRI - September 2026 Quarterly Activities Report and Appendix 4C
TrivarX Limited’s September 2026 Quarterly Activities Report and Appendix 4C outline progr
TrivarX Ltd (TRI)
30 Oct 2026 | 8:56 AM
TRI - Syntro Health Appointed to Support Stabl-Im Clinical Program
TrivarX Limited announced that it has engaged Australian pharmaceutical manufacturing spec
TrivarX Ltd (TRI)
22 Oct 2026 | 9:37 AM
TRI - Stabl-Im Clinical Development Update
TrivarX Limited provided a clinical development update on its Stabl-Im stable isotope-enha
TrivarX Ltd (TRI)
23 Sep 2026 | 9:36 AM
TRI - Appendix 4E - Preliminary Final Report
TrivarX Limited’s Appendix 4E Preliminary Final Report for the financial year ended 30 Jun
TrivarX Ltd (TRI)
27 Aug 2026 | 1:05 PM

TrivarX Ltd (TRI) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 September 2026 Quarterly Activities Report and Appendix 4C 30 Oct 2026 8:56AM $0.008 $0.011 risen by 37.50%
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 Letter to Shareholders & Notice of AGM & Proxy Form 27 Oct 2026 12:36PM $0.008 $0.011 risen by 37.50%
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 Syntro Health Appointed to Support Stabl-Im Clinical Program 22 Oct 2026 9:37AM $0.008 $0.011 risen by 37.50%
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 Change of Director's Interest Notice - David Trimboli 14 Oct 2026 3:40PM $0.010 $0.011 risen by 10%
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 Change of Director's Interest Notice - Chris Ntoumenopoulos 14 Oct 2026 3:39PM $0.010 $0.011 risen by 10%
TrivarX Ltd (TRI)
ORDINARY FULLY PAID
Health Care $13 Notification of cessation of securities - TRI 14 Oct 2026 3:34PM $0.010 $0.011 risen by 10%

TRI Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$8.42 -$91.90 48,242.10% 0.00 0.00 0.00% 0.0%
2025A -$0.94 -$0.20 -48.70% 0.00 0.00 0.00% 0.0%
2024A -$1.24 -$0.40 -63.40% 0.00 0.00 0.00% 0.0%

TRI Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
4DMedical Limited (4DX) $1,566M 1.7823 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Artrya Limited (AYA) $468M -0.0450 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Pro Medicus Limited (PME) $20,191M 1.3034 -0.2811 0.2395 76.2106 106.0117 85.5253 0.36% 0.48% 0.59%
TrivarX Ltd (TRI) $12M 482.4211 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

TRI Directors

Name Position Start Date
Dr Anthony (Tony) Keating Executive Director 31 Jul 2024
Mr Christopher Ntoumenopoulos Non-Executive Director 15 Feb 2023
Mr David Edward Trimboli Non-Executive Director, Non-Executive Chairman 25 Aug 2022

TrivarX Ltd (TRI) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
19 Dec 2025 NTOUMENOPOULOS, Christopher Issued Direct Shares 6,250,000 $0.008 $50,000.000
19 Dec 2025 TRIMBOLI, David Issued Indirect Shares 6,250,000 $0.008 $50,000.000
19 Dec 2025 NTOUMENOPOULOS, Christopher Issued Indirect Shares 5,000,000 $0.008 $40,000.000

See all changes in directors' interest & trades for TrivarX Ltd (TRI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

TRI Management

Name Position
Danielle Meyrick Chief Executive Officer
Kai Sun COO
Cameron Jones Joint Company Secretary
Nova Taylor Joint Company Secretary

TRI Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in TrivarX Ltd (TRI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
62,500,000 (5.42%) Daniel Tillett

TRI Calendar of Events

Date Event
28 September 2027 Report (Annual)
26 August 2027 Report (Prelim)
23 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.